Von Hippel–Lindau

1. VHL Gene Overview

• Gene Name: VHL (Von Hippel–Lindau)
• Chromosome Location: 3p25–26
• Type: Tumor suppressor gene
• Normal Function:
  • Encodes the VHL protein (pVHL), which is part of an E3 ubiquitin ligase complex.
  • Targets HIF (Hypoxia-Inducible Factor) for degradation under normal oxygen conditions.
  • Controls angiogenesis, cell growth, and apoptosis.

2. VHL Mutation / Loss

• Pathophysiology:
  • Loss-of-function mutations → HIF accumulation, even in normal oxygen levels → overproduction of VEGF, PDGF, and other growth factors → tumor angiogenesis.
• Consequences:
  • Increased risk of highly vascular tumors.

3. Clinical Syndromes

• Von Hippel–Lindau Disease:
  • Autosomal dominant inherited syndrome
  • Key Tumor Types:

    Tumor	Notes
    Clear cell renal cell carcinoma (ccRCC)	Highly vascular, often bilateral
    Hemangioblastomas (CNS, retina)	Can cause neurological symptoms
    Pheochromocytoma	Catecholamine-producing adrenal tumors
    Pancreatic neuroendocrine tumors (PNET)	Usually non-functioning
    Endolymphatic sac tumors	Rare inner ear tumors

• Sporadic VHL mutations:
  • Occur mainly in clear cell RCC (most common subtype of kidney cancer).

4. Molecular and Therapeutic Implications

• VHL loss → HIF stabilization → VEGF overproduction → target for therapy.
• Targeted therapies:
  • VEGF inhibitors: Bevacizumab (mAb), Pazopanib, Sunitinib, Axitinib (TKIs)
  • mTOR inhibitors: Everolimus, Temsirolimus (indirectly reduce HIF-driven growth)
• Immunotherapy: ICIs like PD-1/PD-L1 inhibitors can be used in advanced ccRCC, though vascular phenotype affects response.

5. Pharmacology / Treatment Notes

• Clear Cell RCC (VHL-deficient):
  • First-line: VEGF-TKIs ± ICIs depending on risk stratification
  • Second-line: mTOR inhibitors or alternative TKIs
• Monitoring:
  • Imaging for renal lesions, CNS hemangioblastomas, and PNETs
  • Biochemical tests for pheochromocytoma (catecholamines)

Key Takeaways:

• VHL is a tumor suppressor that controls HIF degradation.
• Loss of VHL → angiogenesis-driven tumors, mostly renal, CNS, and endocrine.
• Targeted therapy against VEGF/HIF pathway is central to management of VHL-related tumors.